caa a22 4500 475824024 CHVBK 20180406123826.0 cr unu---uuuuu 170329e20000401xx s 000 0 eng 10.1023/A:1018797411812 doi (NATIONALLICENCE)springer-10.1023/A:1018797411812 Time to Treatment and Cost of Thrombolysis: A Multicenter Comparison of tPA and rPA [Elektronische Daten] [Ali Seyedroudbari, E. Kesslcer, Aryan Mooss, Richard Wundeman, Mohan Bala, Daniel Hilleman] Study Objective: This study reports a comparison of the time to treatment and cost of administration of alteplase (tPA) and reteplase (rPA) in patients with acute myocardial infarction (MI). Design: Retrospective chart review.). Setting: Hospital emergency department.). Interventions: A retrospective chart review of 500 MI patients who received alteplase or reteplase was performed. A comparison of time from presentation in the emergency department to start of treatment was performed, and the cost of administration of drugs, including cost of supplies, monitoring time, and IV line complications, was calculated for each drug.). Results: The time from presentation to start of treatment was significantly shorter for reteplase than alteplase (51 vs 34 min). This difference resulted from a shorter decision to treat to start of treatment time for reteplase (11 min) compared to alteplase (31 min). The cost of administration of alteplase ranged from $136 to $184 per patient, while the cost of administration of reteplase ranged from $87 to $120 per patient.). Discussion: Given the similar safety and efficacy profiles of these thrombolytic agents, the advantages of reteplase in speed of administration and the reduction in cost should be considered when making formulary and drug product selection decisions.). Abbreviated Abstract. Alteplase (tPA) and reteplase (rPA) were compared in a retrospective review of 500 patients. rPA was associated with 17 minute time savings from presentation-to-treatment compared to tPA. rPA was also associated with a per patient cost savings $49 to $64 compared to tPA. The time and cost advantages of rPA should be considered when making drug product selection decisions.). Kluwer Academic Publishers, 2000 reteplase nationallicence alteplase nationallicence thrombolysis nationallicence myocardial infarction nationallicence intravenous injection nationallicence Seyedroudbari Ali Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut Kesslcer E. Bowling Green Medical Center, Bowling Green, KY aut Mooss Aryan Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut Wundeman Richard Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut Bala Mohan Centocor, Inc., Malvern, PA aut Hilleman Daniel Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 9/3(2000-04-01), 303-308 0929-5305 9:3<303 2000 9 11239 https://doi.org/10.1023/A:1018797411812 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1018797411812 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Seyedroudbari Ali Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut NATIONALLICENCE 700 1- Kesslcer E. Bowling Green Medical Center, Bowling Green, KY aut NATIONALLICENCE 700 1- Mooss Aryan Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut NATIONALLICENCE 700 1- Wundeman Richard Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut NATIONALLICENCE 700 1- Bala Mohan Centocor, Inc., Malvern, PA aut NATIONALLICENCE 700 1- Hilleman Daniel Creighton University Schools of Medicine and Pharmacy & Allied Health Professions, Omaha, NE aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 9/3(2000-04-01), 303-308 0929-5305 9:3<303 2000 9 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer